Particle size reduction for improvement of oral absorption of the poorly soluble drug UG558 in rats during early development

References

• Lipinski CJ. (2001). Avoiding investment in doomed drugs. Is poor solubility an industry wide problem? Curr Drug Dis, 4:17–19.
   Google Scholar
• Lipinski CJ. (2002). Poor aqueous solubility—an industry wide problem in drug discovery. Am Pharm Rev, 5:82–5.
   Google Scholar
• Loftsson T, Brewster ME. (1996). Pharmaceutical applications of cyclodextrins. J Pharm Sci, 85:1017–25.
   PubMed Web of Science ®Google Scholar
• Stella VJ, Rajewski RA. (1997). Cyclodextrins: Their future in drug formulation and delivery. Pharm Res, 14:556–67.
   PubMed Web of Science ®Google Scholar
• Akers MJ. (2002). Excipient-drug interactions in parenteral formulations. J Pharm Sci, 91:2283–300.
   PubMed Web of Science ®Google Scholar
• Floyd AG. (1999). Top ten considerations in the development of parenteral emulsions. Pharm Sci Tech, 4:134–43.
   Google Scholar
• Lawrence MJ, Rees GD. (2000). Microemulsion-based media as novel drug delivery systems. Adv Drug Deliv Rev, 45:89–121.
   PubMed Web of Science ®Google Scholar
• Nakano M. (2000). Places of emulsions in drug delivery. Adv Drug Deliv Rev, 45:1–4.
   PubMed Web of Science ®Google Scholar
• Weiner M, Bernstein IL. (1989). Adverse reactions to drug formulation agents. New York: Marcel Dekker.
   Google Scholar
• Gad SC. (2002). Drug safety evaluation. New York: John Wiley and sons.
   Google Scholar
• Nimmerfall F, Rosenthaler J. (1980). Dependence of area under the curve on proquazone particle size and in vitro dissolution rate. J Pharm Sci, 69:605–7.
   PubMed Web of Science ®Google Scholar
• Shastri S, Mroszczak E, Prichard RK, Parekh P, Nguyen TH, Hennessey DR, . (1980). Relationship among particle size distribution, dissolution profile, plasma values and anthelmintic efficacy of oxfendazole. Am J Vet Res, 41:2095–101.
   PubMed Web of Science ®Google Scholar
• Englund DE, Johansson ED. (1981). Oral versus vaginal absorption in oestradiol in postmenopausal women. Effects of different particle size. Ups J Med Sci, 86:297–307.
   PubMed Web of Science ®Google Scholar
• Watari N, Funaki T, Aizawa K, Kaneniwa N. (1983). Nonlinear assessment of nitrofurantoin bioavailability in rabbits. J Pharmacikinet Biopharm, 11:529–45.
   PubMedGoogle Scholar
• Hargrove JT, Maxson WS, Wentz AC. (1989). Absorption of oral progesterone is influenced by vehicle and particle size. Am J Obstet Gynecol, 161:948–51.
   PubMed Web of Science ®Google Scholar
• Amidon GL, Lennernäs H, Shah VP, Crison JR. (1995). A theoretical basis for a biopharmaceutic drug classification: The correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res, 12:413–20.
   PubMed Web of Science ®Google Scholar
• Yu LX, Amidon GL, Polli JE, Zhao H, Mehta MU, Conner DP, . (2002). Biopharmaceutics classification system: The scientific basis for biowaiver extensions. Pharm Res, 19:921–5.
   PubMed Web of Science ®Google Scholar
• Lennernäs H, Abrahamsson B. (2005). The use of biopharmaceutic classification of drugs in drug discovery and development: Current status and future extension. J Pharm Pharmacol, 57:273–85.
   PubMed Web of Science ®Google Scholar
• Kraml M, Dubuc J, Gaudry R. (1962). Gastrointestinal absorption of griseofulvin: II. Influence of particle size in man. Antibiot Chemother, 4:239–42.
   Google Scholar
• Mikota SK, Plumb DC. (2003). Griseofulvin; the Elephant Formulary. www.elephantcare.org [accessed June 06, 2003].
   Google Scholar
• Liversidge GG, Cundy K. (1995). Particle size reduction for improvement of oral bioavailability of hydrophobic drugs: I. Absolute oral bioavailability of nanocrystalline danazol in beagle dogs. Int J Pharm, 125:91–7.
   Web of Science ®Google Scholar
• Liversidge GG, Conzentino P. (1995). Drug particle reduction for decreasing gastric irritancy and enhancing absorption of naproxen in rats. Int J Pharm, 125:309–13.
   Web of Science ®Google Scholar
• Jia L, Wong J, Cerna C, Weitman S. (2002). Effect of nanonization on absorption of 301029: Ex vivo and in vivo pharmacokinetic correlations determined by liquid chromatography/mass spectrometry. Pharm Res, 19:1091–6.
   PubMed Web of Science ®Google Scholar
• Nernst W, Brunner E. (1904). Theorie der reaktionsgeschwindigkeit in heterogenen systemen. Z Physik Chemie, 47, 52–110.
   Google Scholar
• Ziller KH, Rupprecht HH. (1990). Control of crystal growth in drug suspensions. Part II: Influence of polymers on dissolution and crystallization during temperature cycling. Pharm Ind, 52:1017–22.
   Web of Science ®Google Scholar
• Rabinow BE. (2004). Nanosuspensions in drug delivery. Nature Rev, 3:1–12.
   Google Scholar
• Yasueda S, Higashiyama M, Shirasaki Y, Inada K, Ohtori A. (2004). An HPLC method to evaluate purity of a steroidal drug, Ioteprednol etabonate. J Pharm Biomed Anal, 36:309–16.
   PubMed Web of Science ®Google Scholar
• Sigfridsson K, Andersson T, Nilsson L, Schönbacher V, Wang Y. (2007). Pharmaceutical and analytical characterization of (2R)-(3-amino-2-fluoropropyl)sulphinic acid, a GABAB receptor agonist. Eur J Pharm Biopharm, 65:104–10.
   PubMed Web of Science ®Google Scholar
• Dressman JB, Reppas C. (2000). In vitro-in vivo correlations for lipophilic, poorly water-soluble drugs. Eur J Pharm Sci, 11:73–80.
   PubMed Web of Science ®Google Scholar
• Kesisoglou F, Panmai S, Wu Y. (2007). Nanosizing – oral formulation development and biopharmaceutical evaluation. Adv Drug Deliv Rev, 59:631–44.
   PubMed Web of Science ®Google Scholar
• Mouton JW, van Peer A, de Beule K, van Vliet A, Donnelly JP, Soons PA. (2006). Pharmacokinetics of intraconazole and hydroxyitraconazole in healthy subjects after single and multiple doses of a novel formulation. Antimicrob Agents Chemother, 50:4096–102.
   PubMed Web of Science ®Google Scholar
• Xiong R, Lu W, Li J, Wang P, Xu R, Chen T. (2008). Preparation and characterization of intravenously injectable nimodipine nanosuspension. Int J Pharm, 350:338–43.
   PubMed Web of Science ®Google Scholar